MarketPulse

non-invasive treatment

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Oculis Holding Ag

Oculis Eyes DME Market With First Eye Drop Therapy as ARVO Data Show Unmet Need

Oculis' DME AWARE study confirms expert demand for non-invasive treatment; OCS-01 eye drops target June 2026 Phase 3 results as potential first-in-class DME therapy.
OCSOCSAWdiabetic macular edemanon-invasive treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Oculis Holding Ag

Oculis Eyes DME Market Opportunity as Study Reveals 60% Patient Non-Treatment Rate

Oculis-backed research reveals significant unmet needs in diabetic macular edema treatment, with 60% of patients remaining untreated due to invasive therapies.
OCSOCSAWdiabetic macular edemanon-invasive treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis to Showcase Late-Stage Pipeline at ARVO 2026 as OCS-01 Phase 3 Data Nears

Oculis to present advancing ophthalmology pipeline at ARVO 2026, with Phase 3 OCS-01 DME results expected June 2026.
OCSOCSAWPhase 3 clinical trialdiabetic macular edema
GlobeNewswire Inc.GlobeNewswire Inc.··Nexalin Technology, Inc.

Nexalin's Brain Stimulation Tech Shows Promise for Teen Depression, Self-Injury

Nexalin's DIFS neurostimulation technology reduced self-injury and depression symptoms in female adolescents, per peer-reviewed study published in BMC Psychiatry.
NXLclinical trialneurostimulation
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Anti-Snoring Device Market Poised to Double by 2033 Amid Health Awareness Surge

Global anti-snoring devices market projected to nearly double to $3.36 billion by 2033, driven by obesity, health awareness, and technological advances.
GSKRMDPHGe-commercemarket growth